Effect of Empagliflozin in diabetic patients with non-alcoholic steatohepatitis

Phase 3

Recruiting

• Conditions: non-alcoholic steatohepatitis.; Nonalcoholic steatohepatitis (NASH); K75.81

• Registration Number: IRCT20210609051526N2
• Lead Sponsor: Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 November 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

Body mass index less than 35 Kg/mm
No history of chronic alcohol usage
No history of viral hepatities
No history of autoimmune hepatitis
No history of drug-induced hepatitis
No history of chronic usage of hepatic-steatosis-induced drugs(e.g.: Amiodarone, Valproate, Tamoxifen, Methotrexate, Glucocorticoids)
No history of chronic usage of Thiazolidines and GLP-1 agonists
Absence of evidence suggestive for cirrhosis based on physical examination, laboratory evaluation, and imaging studies
Absence of evidence suggestive for Hepatocellular carcinoma based on physical examination, laboratory evaluation, and imaging studies
Non pregnant women
No previous history of HELLP syndrome in women
No history of chronic kidney disease
No history of chronic usage of Omega-3 containing supplements
No contraindication for Empagliflozin usage (e.g.: history of recurrent genitourinary tract infection, gangrene, history of allergic reaction to the drug, serum Trigliceride level more than 500 mg/dl)

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified